Sinaa Al-Aqeel
Sinaa Al-Aqeel
Introduction: The Saudi government, similar to any other government, is committed to making public spending more efficient, using resources more effectively, and limiting waste. Health technology assessment (HTA) is a too...
How can multi criteria decision analysis support value assessment of pharmaceuticals? - Findings from a systematic literature review [0.03%]
多准则决策分析如何支持药物价值评估？系统文献综述的发现
Katarzyna Kolasa,Vladimir Zah,Marta Kowalczyk
Katarzyna Kolasa
Introduction: As budget constraints become more and more visible, there is growing recognition for greater transparency and greater stakeholders' engagement in the pharmaceuticals' pric-ing&reimbursement (P&R) decision ma...
Rare diseases in Romania - a response to 'transposition and implementation of EU rare diseases policy in Eastern Europe' [0.03%]
罗马尼亚的罕见疾病——对“欧盟东欧国家罕见疾病的政策转换和落实”的回应
Emilia Severin
Emilia Severin
Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs [0.03%]
免疫肿瘤药物时代的性价比与支付能力问题比较
George Dranitsaris,Xiaofu Zhu,Georges Adunlin et al.
George Dranitsaris et al.
After years of setback, cancer immunotherapy has begun to yield clinical dividends, which are changing the treatment landscape and offering cancer patients the potential for long-term survival, reduced treatment-related toxicity and improve...
Association of diabetes diagnosis with dietary changes and weight reduction [0.03%]
糖尿病诊断与饮食变化和体重减轻之间的关系
Daeho Kim,Kanghyock Koh,Shailender Swaminathan et al.
Daeho Kim et al.
Background: Lifestyle modifications are associated with better outcomes for patients with diabetes. Patients' awareness of having diabetes may promote lifestyle changes, but there is limited evidence to support this asser...
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study [0.03%]
APICE研究：一项关于nal-PACLITAXEL联合吉西他滨对比单用吉西他滨治疗转移性胰腺癌患者的意大利成本效益分析
Carlo Lazzaro,Carlo Barone,Francesco Caprioni et al.
Carlo Lazzaro et al.
Background: the APICE study evaluates the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel - Nab-P) + gemcitabine (G) vs G alone in metastatic pancreatic cancer (MPC) from the Italian National H...
Optimizing skin and skin structure infection outcomes: considerations of cost of care [0.03%]
皮肤及皮肤软组织感染的治疗效果优化：治疗成本考量
S S Almarzoky Abuhussain,K J Goodlet,M D Nailor et al.
S S Almarzoky Abuhussain et al.
Introduction: Skin and skin structure infections (SSSIs) refer to a collection of clinical infectious syndromes involving layers of skin and associated soft tissues. Although associated with less morbidity and mortality t...
Balancing patient value and payer cost in hematologic malignancies: can it be done? [0.03%]
兼顾患者价值和支付者成本的血液系统恶性肿瘤治疗：可以实现吗？
Pamela B Allen,Christopher R Flowers
Pamela B Allen
Cost-effectiveness thresholds: methods for setting and examples from around the world [0.03%]
成本效果界值：设定方法及其全球实例分析
André Soares Santos,Augusto Afonso Guerra-Junior,Brian Godman et al.
André Soares Santos et al.
Introduction: Cost-effectiveness thresholds (CETs) are used to judge if an intervention represents sufficient value for money to merit adoption in healthcare systems. The study was motivated by the Brazilian context of HT...
Access to anti-cancer drugs in India: is there a need to revise reimbursement policies? [0.03%]
印度抗癌药物的获取：是否需要修订报销政策？
Gertruud Haitsma,Himanshu Patel,Parthasarathi Gurumurthy et al.
Gertruud Haitsma et al.
Background: The aim of this study was to examine the access of Indian cancer patients to optimum cancer care under selected government schemes by reviewing reimbursement schemes for cancer care in India. ...